Auto T cells expressing chimeric antigen receptor derived from auto antibody might be a new treatment for osteosarcoma

Medical Hypotheses

Volumn 78, Issue 5, 2012, Pages 616-618

  Weibo, Pan ^a,b   Zhaoming, Ye ^a  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b TAIZHOU UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AUTOANTIBODY; CHIMERIC ANTIGEN RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN; MONOCLONAL ANTIBODY; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ANTIGEN RECOGNITION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; GENE EXPRESSION; GENETIC MANIPULATION; HUMAN; IMMUNE SYSTEM; IMMUNOGENICITY; NONHUMAN; OSTEOSARCOMA; OSTEOSARCOMA CELL; PHAGE DISPLAY; PROCEDURES; SURVIVAL TIME; T LYMPHOCYTE; TUMOR CELL;

ANTIGENS, NEOPLASM; AUTOANTIBODIES; AUTOIMMUNITY; BONE NEOPLASMS; HUMANS; IMMUNOTHERAPY; MODELS, IMMUNOLOGICAL; OSTEOSARCOMA; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES;

EID: 84859270420     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2012.01.038     Document Type: Article

References (18)

1. Marsh B., Flynn L., Enneking W. Immunologic aspects of osteosarcoma and their application to therapy. A preliminary report. The Journal of Bone and Joint Surgery American Volume 1972, 54(7):1367-1397.
2. Meyers P.A., Schwartz C.L., Krailo M.D., Healey J.H., Bernstein M.L., Betcher D., et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival-a report from the Children's Oncology Group. Journal of Clinical Oncology 2008, 26(4):633-638.
3. Tsukahara T., Kawaguchi S., Torigoe T., Asanuma H., Nakazawa E., Shimozawa K., et al. Prognostic significance of HLA class I expression in osteosarcoma defined by anti-pan HLA class I monoclonal antibody, EMR8-5. Cancer Science 2006, 97(12):1374-1380.
4. Endo-Munoz L., Cumming A., Sommerville S., Dickinson I., Saunders N.A. Osteosarcoma is characterised by reduced expression of markers of osteoclastogenesis and antigen presentation compared with normal bone. British Journal of Cancer 2010, 103(1):73-81.
5. Eshhar Z., Waks T., Gross G., Schindler D.G. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors. Proceedings of the National Academy of Sciences of the United States of America 1993, 90(2):720-724.
6. Ahmed N., Salsman V.S., Yvon E., Louis C.U., Perlaky L., Wels W.S., et al. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Molecular Therapy: The Journal of the American Society of Gene Therapy 2009, 17(10):1779-1787.
7. Brentjens R.J., Riviere I., Park J.H., Davila M.L., Wang X., Stefanski J., et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011, 118(18):4817-4828.
8. Katari U.L., Keirnan J.M., Worth A.C., Hodges S.E., Leen A.M., Fisher W.E., et al. Engineered T cells for pancreatic cancer treatment. HPB (Oxford) 2011, 13(9):643-650.
9. Ahmed N., Salsman V.S., Kew Y., Shaffer D., Powell S., Zhang Y.J., et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2010, 16(2):474-485.
10. Ertl H.C., Zaia J., Rosenberg S.A., June C.H., Dotti G., Kahn J., et al. Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010. Cancer Research 2011, 71(9):3175-3181.
11. Ramos C.A., Dotti G. Chimeric antigen receptor (CAR)-engineered lymphocytes for cancer therapy. Expert Opinion on Biological Therapy 2011, 11(7):855-873.
12. OBA - RAC Meetings - 2000 to 2009. http://www.oba.od.nih.gov/rdna_rac/rac_past_meetings_2000.html.
13. Jena B., Dotti G., Cooper L.J. Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 2010, 116(7):1035-1044.
14. Jensen M.C., Popplewell L., Cooper L.J., DiGiusto D., Kalos M., Ostberg J.R., et al. Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 2010, 16(9):1245-1256.
15. Eilber F.R., Morton D.L. Demonstration in sarcoma patients of anti-tumor antibodies which fix only human complement. Nature 1970, 225(5238):1137-1138.
16. Liao B., Ma B., Liu Z., Zhang H., Long H., Yang T., et al. Serological identification and bioinformatics analysis of immunogenic antigens in osteosarcoma. Cancer Biology & Therapy 2007, 6(11):1805-1809.
17. Morton D.L., Malmgren R.A. Human osteosarcomas: immunologic evidence suggesting an associated infectious agent. Science 1968, 162(3859):1279-1281. (80-).
18. Dantas-Barbosa C., Faria F.P., Brigido M.M., Maranhao A.Q. Isolation of osteosarcoma-associated human antibodies from a combinatorial Fab phage display library. Journal of Biomedicine & Biotechnology 2009, 2009:157531.